Alembic Pharmaceuticals Limited (APL) has posted a 12 per cent growth in net profit for the quarter ended March 31, to Rs 251 crore, from Rs 225 crore during the corresponding period last year. The company s net sales were up six per cent to Rs 1,280 crore, from Rs 1,207 crore. On a full-year basis, the company s net profit rose 42 per cent to Rs 1,178 crore for FY21, from Rs 829 crore in FY20, while net sales were up 17 per cent to Rs 5,393 crore (Rs 4,606 crore). Commenting on the results, Alembic Pharmaceuticals Limited managing director Pranav Amin said the fiscal was an outstanding year , with the company recording its highest-ever sales and profit. This was led by strong growth in the API and international businesses. The operating teams worked tirelessly through the pandemic to ensure critical supplies were uninterrupted, Amin added.
Alembic Pharmaceuticals Ltd Q4FY21 consolidated net profit drops QoQ to Rs 237 41 crores
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Alembic Pharmaceuticals announces USFDA Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Aleor Dermaceuticals receives USFDA Tentative Approval for Efinaconazole Topical Solution, 10%
Posted On: 2021-04-07 22:47:15 (Time Zone: Arizona, USA)
Alembic Pharmaceuticals Limited (Alembic) today announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Efinaconazole Topical Solution, 10% has an estimated market size of US$ 233 million for twelve months ending December 2020 according to IQVIA. Aleor has settled the case with Bausch Health and. will launch its generi